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Background: Providing compensation for participants in clinical research is well established and while inter-
national guidelines exist, defining a context-specific and fair compensation for participants in low-resource set-
tings is challenging due to ethical concerns and the lack of practical, national compensation and reimbursement
frameworks.
Methods: We reviewedOxford University Clinical Research Unit (OUCRU) internal reimbursement documentation
over a 10-y period and conducted a scoping literature review to expand our knowledge of compensation and
reimbursement practices including ethical concerns. We developed a preliminary reimbursement framework
that was presented to community advisory boards (CAB) and clinical investigators to assess its applicability,
fairness and transparency.
Results: The main topics discussed at the workshops centered on fairness and whether the reimbursements
could be perceived as financial incentives. Other decisive factors in the decision-making process were altruism
and the loss of caregivers’ earnings. Investigators raised the issue of additional burdens, whereas the CABmem-
bers were focused on non-monetary elements such as the healthcare quality the patients would receive. All
elements discussed were reviewed and, where possible, incorporated into the final framework.
Conclusion: Our new reimbursement framework provides a consistent, fair and transparent decision-making
process and will be implemented across all future OUCRU clinical research in Vietnam.
Keywords: ethics, LMICs, participant compensation, participant reimbursement, remuneration framework, Vietnam.
Introduction
Providing compensation for participants in clinical research is a
well-established practice, although defining a fair and appro-
priate amount remains a challenge and is still an area of de-
bate.1,2 Researchers are guided by international guidelines such
as the Council for International Organizations of Medical Sciences
(CIOMS) statements and existing frameworks, but there is a need
for enhanced transparency, greater consistency across research
programs and practical models.3–5
For many years, discussions on the ethical issues surrounding
participant payments have been ongoing, particularly related to a
disproportionate research burden on vulnerable populations, co-
ercion (pressure or intimidation) and undue influence, when an
attractive offer affects a person’s ability to make an informed
decision.6,7 In low and middle income countries (LMICs), defin-
ing a context-specific and fair compensation for participants is
challenging due to structural healthcare inequalities, pertinent
ethical concerns and conflicting arguments about vulnerable
populations, including aspects of economic disadvantages.1
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Ethics committees have previously recommended that payments
be kept low to avoid influencing participation by attracting partic-
ipants through payment incentives.8,9 However, refraining from
giving cash payments to poorer populations is not only unfairly
discriminative, but this risks making samples within clinical re-
search unrepresentative and it could be detrimental to recruit-
ment if participants cannot afford to take part because their loss
of earnings are not reimbursed.2,10
The Oxford University Clinical Research Unit (OUCRU) has con-
ducted many research projects and clinical trials since its imple-
mentation in Vietnam in 1991 (http://www.oucru.org). Through
a review of 134 studies conducted over the last 10 y, the clinical
trials unit (CTU) reimbursement working group identified a lack of
consistency and transparency in compensation of participants.
Furthermore, OUCRU’s reimbursement policy, last amended in
2013, sets a lump sum based on the participant’s place of ori-
gin to cover a return journey using a public mode of transport,
either bus or train. Due to the severity of participants’ conditions
and occasionally cultural practices, participants often travel with
relatives or caregivers, who frequently receive travel reimburse-
ments as well. In absence of clear guidelines for reimbursements
of non-participants, travel reimbursements cannot be accurately
budgeted for, and this tends to be a contributor to overspent bud-
gets in many studies.
Therefore, a standardized system is required to transparently
and ethically justify how much participants in our studies should
be reimbursed and why. The objectives of the present study are
to develop a fair and transparent framework for research partic-
ipant compensation, as well as to amend the current guidelines
for travel reimbursement, with the hope this could help guide
other research units in Vietnam and the wider region.
Materials and Methods
Document and literature review
The CTU reimbursement working group, consisting of eight peo-
ple (three trialists, a medical anthropologist, a quality assurance
manager, a contract manager and two study coordinators), re-
viewed the study protocols and patient information sheets of 134
clinical studies conducted at OUCRU from 2009 to 2019 to iden-
tify the current and past payment methods adopted by the unit
for participants’ compensation and reimbursement (Supplemen-
tary Document 1). The working group agreed to use the following
categories: (1) reimbursement of expenses incurred for trial vis-
its, (2) compensation for participants’ time and burdens experi-
enced in the trial and (3) incentive, either financial or a gift, usu-
ally intended to boost recruitment and retention.5,11 Building on
in-house expertise as well as existing internal guidelines, a com-
pensation framework from 2011 and the OUCRU reimbursement
policy (Supplementary Figure 1), an initial list of key themes for
compensationwas identified: (1) the type of study (interventional
or observational), (2) inpatient or outpatient study visits, (3) stud-
ies involving healthy volunteers, (4) hospitalization for study pur-
poses, (5) risk, (6) invasiveness, (7) disease severity, (8) availability
of treatment alternatives and (9) disease prevalence.
We then conducted a scoping literature review that took place
from March to May 2019, aiming to further expand our knowl-
edge on the themes identified and to explore the ethical con-
cerns associated with participant compensation (Figure 1). We
used the PubMed search tool (no date specified) as well as Google
Scholar (manuscripts from 2010 onwards), only including original
articles and reviews in English with a focus on LMICs. This yielded
483 journal articles. Forty-six records were also identified through
reference lists and recommendations from colleagues. These in-
cluded national and international compensation guidelines. We
found many titles (n=426) to be irrelevant, focusing on compen-
sation for injury, healthcare payment and hospital payment sys-
tems. After removing the duplicates (33 articles that appeared
multiple times across the search terms), we screened 70 remain-
ing titles and abstracts for eligibility. Subsequently, we reviewed
41 full-text papers, of which 32 were considered relevant in ad-
dressing the needs of our framework. Nine were not included; five
of these because they focused on coercion and undue influence.
Although briefly noted, these issues are beyond the scope of this
paper.
Compensation framework
Using the information gathered through the internal document
review and from the literature, we re-examined the nine themes
and their associated ethical concerns. Via an iterative process of
in-house discussions within the CTU working group, we devel-
oped a points-based preliminary framework for compensation
(Supplementary Figure 2). The value attributed for each point
was determined using Oxford Tropical Research Ethics Commit-
tee and the Vietnamese Ministry of Health guidelines, which
recommend that subjects should be compensated for loss of
income, travel expenses and any other indirect losses.12,13 Fur-
thermore, CIOMS suggests that the amount of compensation
should be calculated using the minimum hourly wage in the re-
gion or country as a reference value.3 For Region 1, which includes
Ho Chi Minh City and Hanoi, the minimum wage is 4420000 Viet-
namese Dong (VND), which equals US$180 per month (https://
wageindicator.org/salary/minimum-wage/vietnam). Considering
that people in Vietnam work on average 25.5 days per month,
this represents an approximate daily wage of 173 000 VND (ap-
proximately US$7.50). A value of 100 000 VND (approximately
US$4) per point was considered appropriate as consistent with
payments in OUCRU in the past. This preliminary framework fo-
cused on compensating participants for their loss of earnings and
burdens endured, and deducting points if the participants had
higher disease severity. To measure this objectively, we used the
modified Rankin score (MRS), a validated measure of disability
used across OUCRU studies. A higher MRS score equated to more
points being deducted.
Reimbursement element of the framework
Through review of OUCRU documentation and in-house discus-
sion, it became apparent that reimbursement amounts were be-
ing paid to both participants and their family members/carers in
many cases. This was not factored into the trial budget in the
early stages and caused over-expenditure. Thus, we developed
guidelines based on the participant’s capability to travel alone.
The MRS score was also utilized here as a method of determining
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Figure 1. Diagram illustrating the scoping review results. *PUBMED search (no date specified to ensure comprehensive overview of manuscripts) terms
used in text (and/or) were: ‘reimbursement, participant, clinical trial, patient, compensation, ethics, research, low income’. Search terms used in ti-
tle/abstract were: ‘reimbursement, payment, and remuneration’. Google Scholar search (2010+ to add onlymost recentmanuscripts), which included
the terms used in text: ‘patient compensation in clinical trials, participant reimbursement in clinical trials, participant reimbursement in clinical trials
LMIC, research participation compensation low income setting, compensation reimbursement low resource participant’, as well as terms used in the
title: ‘low income countries research, Vietnam healthcare’.
Workshops
The preliminary points-based compensation and reimburse-
ment framework was first presented in a workshop with pa-
tient representatives from community advisory boards (CAB)
of two active trials (a hepatitis C trial, http://www.isrctn.com/
ISRCTN17100273; and a TB meningitis trial, https://clinicaltrials.
gov/ct2/show/NCT03100786? term = NCT03100786&rank = 1).
Of the 12 attendees, 8 (67%) were involved in the aforemen-
tioned studies and 4 (33%) were relatives and had not been en-
rolled in any studies in the past. In Vietnamese, attendees were
informed about the aims of the project, the ethical concerns
surrounding patient reimbursement and the components of the
framework. An interactive discussion was then conducted using
a set of eight hypothetical scenarios based on the two current
studies to compare current payment schedules with those gen-
erated by the framework (Supplementary Document 2). Using
a questionnaire, we probed and collected attendees’ feedback
on the payment amounts, factors considered in the framework,
travel reimbursement guidelines and motivations to take part in
clinical research (Supplementary Document 3). Another similar
workshop was later presented in English to OUCRU staff. Ten at-
tendees were present: clinicians, trialists, laboratory and pub-
lic engagement managers, who all had first-hand experience
in acting as principal investigators for clinical research. Feed-
back from the workshops led to a revised framework, which was
then applied to 13 ongoing studies to compare the generated
compensation amounts with those defined by the current policy
(Supplementary Document 4). Applying the framework to these
studies allowed us to evaluate its fitness for purpose and to
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defined. This led us to categorize types of burden more ade-
quately and, additionally, we decided to increase the baseline pay
for healthy volunteers before finalizing our compensation and re-
imbursement framework.
RESULTS
The final compensation and reimbursement framework results
from a review of OUCRU internal guidelines, existing literature as
well as the analysis of CAB and OUCRU investigators feedback,
collected during two independent workshops (Figure 2).
Compensation framework
The final compensation framework covers five central questions
related to the design of the study and how it may affect partici-
pants’ wellbeing (Figure 2A). These questions are: (1) What type
of study (interventional or observational) is conducted? (2) Is the
participant a healthy volunteer, who enrolls in a clinical study
with no prospect of medical benefit? (3) Is there any additional
(not standard of care) inpatient hospital stay required per study
protocol? (4) Are outpatient visits (not standard of care) required
by the study protocol? (5) Are the participants subjected to bur-
dens for study purposes only? Typical burdens were categorized
as single- or long-term non-invasive (e.g. tracking devices, ques-
tionnaires, ultrasounds and x-rays) and single or repeated inva-
sive procedures (e.g. blood samples, lumbar punctures and phar-
macokinetic/pharmacodynamic sampling).
Reimbursement element of the framework
The 2013 travel reimbursement policy will now be utilized along-
side the following guidelines:
(1) Participants are only entitled to travel reimbursement if they
traveled to the study site, specifically and only for study
purposes.
(2) Participants with more severe disease or disability conditions
(MRS≥3) and children (aged 2–16 y) are entitled to additional
travel reimbursement to support the cost of caregivers and
parents.
If participants are required to stay overnight, they are entitled to
a maximum of 300 000 VND (approximately US$13) to account
for hotel expenses.
Key decisions and changes between the preliminary
and final framework
First, following review of the current literature, it was apparent
that clinical research should not compensate directly for risk re-
lated to a study procedure. Thus, we incorporated ‘additional bur-
den’ as a factor into the preliminary framework presented at
the workshops; one point for invasive procedures above that of
standard care and one point for time-consuming or burdensome
tasks, such as questionnaires. However, this proved contentious.
CAB members stated that they did not fully comprehend what
constitutes additional burden, such as additional blood volume
or tests above that of routine care. OUCRU investigators stated
that studies conducted at OUCRU vary significantly in the num-
ber of study visits and the number and intensity of study proce-
dures. They felt that the framework presented would not differ-
entiate one study with many non-invasive but time-consuming
tasks from another involving a small number of highly inva-
sive procedures. All clinicians agreed that participants should be
compensated for each burden encountered above that of stan-
dard of care. Following this, typical ‘burdens’ across all OUCRU
research studies were categorised into non-invasive (single- or
repeated/long-term) or invasive (single or repeated) procedures.
Second, the preliminary framework originally incorporatedmi-
nus points into the algorithm to compensate for higher hospital
costs associated with more severe levels of disease, and the hy-
pothesis that these patients are unlikely to be working and there-
fore should not be compensated for loss of earnings. We there-
fore incorporated the MRS in our framework. Participants with
a higher MRS score had more points deducted (Supplementary
Figure 2). This resulted in different payments for patients enrolled
in the same study, as shown in the scenarios 1 vs 2 (Supplemen-
tary Document 2). The CABmembers struggled to understand the
algorithm and half of the attendees disagreed that patients of
differing disease severity should receive less or different financial
compensation in the hypothetical scenarios. They felt that par-
ticipants should either get equal compensation, regardless of the
severity of their disease, or, if anything, that people withmore se-
vere disease should receive more compensation, as they have to
stay longer in hospital. OUCRU investigators agreed with the al-
gorithm but felt that it could be difficult to explain to two patients
in the same study, who might be next to each other on the ward
or in the outpatient clinic, why one person received more com-
pensation than the other. The OUCRU investigators also agreed
that degree of disease severity should not be a factor in financial
compensation. As a result, disease severity was removed from
the framework and payment wasmade consistent across all par-
ticipant arms.
Third, the preliminary framework awarded an additional point
if the safety profile of the intervention was not well known. This
raised questions in the OUCRU investigator workshop as some in-
terventions’ safety profiles are well known but not in the context
in which they are to be used. Additionally, the original 2011 OU-
CRU guidelines show higher payments for interventional studies.
Therefore, one point was awarded at baseline for interventional
trials in the final framework instead.
Last, the preliminary framework included a multiplication fac-
tor for interventional studies (X2). This additional step proved to
be an unnecessary complication and, instead, the final frame-
work has a point value of 100000 VND (approximately US$4)
rather than 50000 VND (approximately US$2) and a baseline pay-
ment for interventional studies (as discussed).
General feedback on participant compensation
amounts
After discussion of the preliminary framework and working
through the different scenarios, the CAB members felt that the
proposed compensation amountswere fair inmost of the scenar-
ios. Interestingly, one person felt that using the minimum wage
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Figure 2. Final OUCRU compensation framework. (A) Point-based compensation framework designed to determine the amount participating patients
are entitled to. The framework focuses on five key components: type of study, type of patient, hospital length of stay, study specific visit and burden.
(B) Reimbursement section designed to determine whether reimbursement is given to patient and a familymember/carer or an adult if the participant
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scales for government employees should be used. Another pa-
tient representative felt that the compensation amount was too
low to cover costs for each follow-up visit. Consistent with this,
OUCRU investigators said that follow-up visit payments of 50 000
VND (approximately US$2) were too low for the participants’ time
but agreed that it is an appropriate gesture as most OUCRU stud-
ies currently do not give any compensation on top of travel re-
imbursement. One investigator, however, commented that they
have experienced loss to follow-up as relatives refuse to accom-
pany the participant on follow-up visits. Although travel reim-
bursement is offered for both the participant and the carer, the
carer does not want to lose a day’s wages. Notably, and of great
importance, the CAB members confirmed that in the context of
the tested scenarios, the financial factor did not represent the pri-
mary motivation. They stated that their main motivation to par-
ticipate would be to learn more about the disease they had and
to help others in the community.
Travel reimbursement
Workshop attendees were overall satisfied with the proposed re-
imbursement guidelines. One CABmember suggested that travel
time should be included in the reimbursement value. This sug-
gestion was debated but, given that the amount reimbursed to
participants is higher than the actual cost of public transport to
a hospital in Ho Chi Minh City, the CTU working group felt this
covered both costs as well as travel time and hence this was not
included in the final framework. Additionally, the OUCRU investi-
gators agreed that certain conditions, such as pregnancy or lim-
ited vision, may not fall into the predefined MRS, but still require
a relative to accompany the participant. In such situations, the
principal investigator has the flexibility to make the final decision
regarding the travel reimbursement amount.
Discussion
A consensus in the literature is that reimbursement for incurred
costs such as transport, subsistence and accommodation as
well as compensation for time and burden is acceptable, and
often encouraged, as long as it is not so high as to coerce a
participant.2,4–6,14 The final framework covers both travel reim-
bursement and participant compensation as agreed upon by the
CAB and the OUCRU investigators; however, several remunera-
tion models incorporate an element of incentive to participate or
a form of appreciation.1,2,4,5 While the working group acknowl-
edges that financial incentives can send participants a strong
message that researchers value their time and increases their
willingness to participate, the concern of ‘undue inducement’ is
present and particularly heightened in the context of structural
inequalities existing in LMICs.8,15–17 On the other hand, stopping
participants from receiving compensation in LMICs can act as a
hindrance to study recruitment, as studies conducted in Kenya
showed that low payments to participants from families reliant
on subsistence forms of livelihood can impact the ability of bread-
winners to feed their families.11,18
After discussing whether to add this element to the frame-
work, the working group opted not to include financial incen-
tives. In addition to a limited level of ‘recruitment competition’,
the inducement issuesmentioned above are further complicated
by contexts with structural inequalities, where access to health-
care is limited and decisions are less driven by individual choice
or money, and more by the prospect of healthcare. Studies have
shown that access to high-quality treatment, which is otherwise
unaffordable or unavailable, is a contributing factor to participat-
ing in research in LMIC settings, despite the possibility of receiv-
ing a placebo or unknown side effects.19–21 Consequently, this
raises concerns that attractive medical benefits can cause coer-
cion because participants have no alternative choice or are per-
ceived as ‘an empty choice’, as first described by Kingori.22 We felt
this was less of an issue in Vietnam, where healthcare is avail-
able and a health insurance scheme was introduced in 1993,
which aimed for a target of 90% coverage by 2020.23 In addition
to monetary compensation and healthcare benefits, wanting to
contribute to research was often mentioned.24 Results from the
CAB workshop support the studies conducted by Njue et al. and
Shah et al., who reported that patient representatives agreed that
participants could not be financially persuaded to take part and
that they wanted to contribute to research to help people in their
communities.24,25
Throughout the development of the framework, the work-
ing group wanted to consider other factors that could influence
a participant’s willingness or motivation to participate. We did
not want to lose sight of the importance of our local setting
and cultural aspects that could impact participant remuneration
procedures. Studies in Kenya and Gambia saw financial bene-
fits as problematic; for example, men felt suspicious about re-
ceiving cash to compensate for blood samples and this made
them wonder about the real use of their blood.11,18,26 Similarly,
women felt uncomfortable with the compensation received for
their participation, knowing it would likely result in conflict with
their spouses.11 Although suspicions surrounding financial com-
pensation do exist in Vietnam, this seems to be perceived as
more problematic by clinicians and less so by participants. Viet-
nam is also more liberal in terms of gender hierarchy, however,
in some Asian cultures, it is unheard of, or even frowned upon,
for a woman to travel without her partner.27,28 For the working
group it was important to consider the distance that participants
may be required to travel, and older generations (women in par-
ticular) might not feel comfortable traveling alone. The OUCRU
travel policy reimburses a set amount according to the province
where the participant lives/is traveling from (i.e. the participant is
not required to retain receipts for reimbursement). This allows for
flexibility in that they can use that money to travel via the mode
that suits them, for example, by car or motorbike, or with a rela-
tive if they prefer to have company.
In addition to unpacking the content and meaning of bur-
den and disease severity for our remuneration framework, we re-
viewed other elements in the research process such as a complex
informed consent process. This is beyond the scope of this paper
and is being explored in other OUCRU research projects.28 Finally,
we wanted to highlight the inclusion of ‘healthy volunteers’ as
an element in the framework. These volunteers are exposed to
the risk and discomfort of research without the potential or ex-
pectation of health benefits. Since there is no medical incentive
for the participant often the primary motivation seems to be fi-
nancial reward but again the literature shows that in this context
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important motivators.25,29–33 We intend to apply this framework
to planned human challenge studies involving healthy partici-
pants and, if appropriate, revise andadapt our current framework.
Conclusions
The framework provides a transparent, fair and consistent
method of calculating compensation for research participants by
itemizing factors that contribute to the total amount. This tool
can be used across all OUCRU clinical research and is a means
of providing justification for the payment to local and interna-
tional ethics committees. It is not only practical in its use but is
also underpinned by sound ethical considerations with acknowl-
edgment of elements important to study teams and participants
such as additional burdens and disease severity. Engaging the
CAB and the OUCRU investigators in the development process
of this framework was extremely valuable and helped the reim-
bursement working group to gain understanding of and insight
into the lived experiences of participants and study teams with
regard to research participation and compensation.
This framework can be applied to other clinical trials units in
Vietnam and our OUCRU units in Indonesia and Nepal. Currency
values to substitute points should stay in line with CIOMS guide-
lines that state compensation should reflect the minimum wage
in a particular country.
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Supplementary data are available at International Health online.
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